Aclarion, a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the first patient enrollment in the CLARITY (C hronic L ow b A ck pain R andomized I ndependent T rial stud Y) trial evaluating Nociscan’s clinical and economic value in spine surgery. The first patient was enrolled at the Texas Back Institute.
Jeffrey Lotz, PhD, is the lead UCSF inventor.